Physician profile
Stephan Simonian
NPI 1104924208
$14,953.59
in general payments reported to CMS, 2019-2025
24 companies · $2,899 in 2025
The $2,899 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,900 · 2020: $860 · 2021: $1,736 · 2022: $2,303 · 2023: $3,022 · 2024: $2,234 · 2025: $2,899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,154.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $3,857.39 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Abbvie INC. | $2,256.79 | 2021-2025 | Vraylar |
| Vanda Pharmaceuticals INC. | $1,888.32 | 2019-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $1,799.72 | 2019-2025 | Aristada, Lybalvi |
| Allergan, INC. | $1,316.33 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $798.70 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Mycite |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $631.44 | 2020-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $518.15 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $379.86 | 2019-2024 | Rexulti |
| Almatica Pharma LLC | $239.04 | 2023-2025 | Loreev Xr |
| Teva Pharmaceuticals USA, INC. | $237.05 | 2019-2024 | Uzedy, Austedo Xr, Austedo |
| Idorsia Pharmaceuticals US INC | $220.52 | 2022-2025 | Quviviq, Quviviq |
| Ironshore Pharmaceuticals INC. | $216.19 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $134.72 | 2019-2022 | |
| Axsome Therapeutics, INC. | $90.09 | 2025 | Auvelity |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $77.51 | 2023-2025 | Qelbree, Qelbree |
| Noven Therapeutics, LLC | $61.68 | 2020-2024 | Xelstrym |
| Luye Pharma (USA) Ltd. | $56.54 | 2025 | Erzofri Extended-Release |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $50.00 | 2019 | |
| Eisai INC. | $37.58 | 2020 | |
| Lilly USA, LLC | $29.45 | 2022 | |
| Sunovion Pharmaceuticals INC. | $25.28 | 2020 | |
| Indivior INC. | $16.82 | 2021 | |
| Neurocrine Biosciences, INC. | $14.42 | 2024 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephan Simonian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.